Despite the advancements of EGFR-TKI-targeted anticancer drugs in the treatment of NSCLC, EGFR-TKI-associated cardiotoxicities including on-target toxicity and off-target toxicity are evident in some patients, such as symptomatic congestive heart failure (CHF), asymptomatic left ventricular (LV) dysfunction, or QT interval prolongation (Force et al., 2007; Chen et al., 2008). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.